Omicron and vaccines: An analysis on the decline in COVID-19 mortality
Larrauri, B.; Malbran, A.; Larrauri, J. A.
Show abstract
The SARS-CoV-2 virus emerged in December 2019 infecting more than 430 million people worldwide and causing almost 6 million deaths until February 2022. Rapid vaccination efforts during this period coincided with a reduction in the mortality rate of the virus. A new genetic COVID-19 variant named Omicron appeared and widely spread by the end of 2021, after which the COVID-19 mortality rate showed a marked, albeit temporary, decline. The potential relationship between vaccines and omicron infection on the mortality rate of COVID-19 is analyzed in this article using online data from public sources from countries with relatively high incidence of infection. Mortality and incidence rates were compared before and after Omicron became the prevalent source of COVID-19 cases, as well as the effect of vaccination during these periods. Infection rates were higher during Omicron than in the pre-Omicron period (4.16% vs. 2%, respectively), whereas mortality rates showed the opposite trend both in deaths over population (0.021% vs. 0.171%) and deaths over positive cases (0.27% vs. 1.07%, respectively). The results suggest that vaccines, while significantly reducing mortality, did not prevent Omicron infection; and that during the Omicron period mortality decreased by a low aggressiveness of this variant. Key Messages* Vaccines do not appear to have prevented Omicron infection. * Infection rates were higher during the Omicron period than before it. * Mortality rates were lower during the Omicron period than before it. * Vaccines reduced mortality rates during both pre- and Omicron periods. * The sharp decrease in mortality rates during the Omicron period seems to be due to the low virulence of Omicron strains rather than vaccine efficacy.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China 93%
- Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study 93%
- Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222 93%
Similar papers in this journal
- COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: a multi-country cross-sectional study 93%
- The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe 93%
- Public opinion on global distribution of COVID-19 vaccines: evidence from two nationally representative surveys in Germany and the United States 93%
Similar papers in this journal
- Previous COVID-19 infection and antibody levels after vaccination 94%
- Determinants of SARS-CoV-2 Vaccine Engagement in Algeria: A Population-based Study with Systematic Review of Studies from Arab Countries of the MENA Region 92%
- Projecting the impact of SARS-CoV-2 variants on the COVID-19 epidemic and social restoration in the United States: a mathematical modelling study 92%
Similar papers in this journal
- Can individuals with low antibody responses to vaccines against other viruses acquire adequate SARS-CoV-2 antibody after vaccination with the BNT162b2 mRNA vaccine? 93%
- Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS-CoV-2 Spike protein after natural infection or COVID-19 vaccination 93%
- Limited impact of Delta variant’s mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.